Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy

Kumar, Anuj; Das, Soma; Mullick, Ranajoy; Lahiri, Priyanka; Tatineni, Ranjitha; Goswami, Debashree; Bhat, Prasanna; Torresi, Joseph; Gowans, Eric J.; Karande, Anjali A.

doi:10.1016/j.vaccine.2015.11.061

Cited by 23 publications

(43 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…: core, GU172376; E1E2, GU172375) and HCV-LP generated as described earlier [45,46]. Similarly, the core-E1-E2 of gt1b was amplified from replicon Con 1FL (accession no.…”

Section: Generation and Purification Of Baculovirus-based Hcv-lpsmentioning

confidence: 99%

“…Similarly, the core-E1-E2 of gt1b was amplified from replicon Con 1FL (accession no. AJ238799) [47] and HCV-LP for gt1b was generated as mentioned earlier [45,46]. To generate HCV-LPs, Sf21 cells were infected with recombinant baculovirus (at an m.o.i.…”

Section: Generation and Purification Of Baculovirus-based Hcv-lpsmentioning

confidence: 99%

“…After 72 h, cell pellets were washed three times with PBS (50 mM phosphate buffer, pH 7.2, containing 150 mM NaCl) and were resuspended in lysis buffer (50 mM NaCl, 50 mM Tris, 0.5 mM EDTA, 1 mM PMSF, 0.1 % Nonidet P-40 and 0.25 % protease inhibitors) using a homogenizer. The lysate was centrifuged and HCV-LPs were purified using sucrose gradient ultracentrifugation [45,46]. The HCV-LPs (both gt3a and gt1b) were characterized by ELISA and confirmed by electron microscopy [45,46].…”

Section: Generation and Purification Of Baculovirus-based Hcv-lpsmentioning

confidence: 99%

“…The lysate was centrifuged and HCV-LPs were purified using sucrose gradient ultracentrifugation [45,46]. The HCV-LPs (both gt3a and gt1b) were characterized by ELISA and confirmed by electron microscopy [45,46].…”

Section: Generation and Purification Of Baculovirus-based Hcv-lpsmentioning

confidence: 99%

See 3 more Smart Citations

Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies

Das

Mullick

Kumar

et al. 2017

Journal of General Virology

Self Cite

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is a leading cause of chronic viral hepatitis, but an effective vaccine is still not available to prevent infection. Use of neutralizing antibodies could be a potential therapeutic option. In this study, the presence of anti-HCV antibodies in HCV-infected patients was assessed from 50 patients and the presence of neutralizing antibodies was examined using 'hepatitis C virus-like particles'. Antibodies from two samples exhibited significant inhibitory activity, suggesting that these may neutralize viral infection. Antigenic determinants generating the neutralizing antibodies from these two samples were delineated by epitope mapping using the core, E1 and E2 regions and a stretch of 45 amino acid peptide (E2C45) derived from the C-terminal region of HCV-E2 protein (aa 634-679) was designed. Results suggest that this hitherto uncharacterized region has the potential to generate neutralizing antibodies against HCV and thus be effective in preventing virus entry into liver cells. Computational analysis of the structure of the modelled peptide (E2C45) suggested high conformational entropy for this region. Furthermore, E2C45 peptide-generated antibodies could block virus entry and monoclonal antibodies generated against this peptide could also significantly reduce virus replication in a cell culture system. It is possible that the inhibition could be partly due to a conformational alteration of the CD81-binding region, preventing virus attachment to liver cells. In conclusion, this work focused on the discovery of a novel epitope at the C terminus of E2 that induces potent neutralizing antibodies in HCV-infected patients.

show abstract

“…: core, GU172376; E1E2, GU172375) and HCV-LP generated as described earlier [45,46]. Similarly, the core-E1-E2 of gt1b was amplified from replicon Con 1FL (accession no.…”

Section: Generation and Purification Of Baculovirus-based Hcv-lpsmentioning

confidence: 99%

Section: Generation and Purification Of Baculovirus-based Hcv-lpsmentioning

confidence: 99%

Section: Generation and Purification Of Baculovirus-based Hcv-lpsmentioning

confidence: 99%

Section: Generation and Purification Of Baculovirus-based Hcv-lpsmentioning

confidence: 99%

See 2 more Smart Citations

Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies

Das

Mullick

Kumar

et al. 2017

Journal of General Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, results of Kumar et al [40] suggested that the combined regimen of HCV viral-like particles followed by recombinant adenovirus could more effectively inhibit HCV infection, endorsing the novel vaccine strategy.…”

Section: Hcv-viral Like Particles (Vlp)mentioning

confidence: 99%

Progress in Vaccine Development for HCV Infection

Tabll¹,

El‐Shenawy²,

El³

2017

Update on Hepatitis C

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is a blood-transmitted disease that spreads among 3% of the world's population causing seriously increasing mortality rates. The HCV prevalence in Egypt in October 2008 was 14.7% and declined to 6.3% in the survey carried out in October 2015. Nowadays, the new direct-acting antivirals (DAAs) show amazing results especially with regard to HCV genotype 1, but there is still a great necessity to produce a vaccine to avoid this viral infection. Additionally, neutralizing anti-HCV antibodies could be utilized in combination with DAAs empowering their effect. A powerful candidate HCV vaccine should create comprehensively cross-receptive T cells CD4 and CD8 and effectively neutralizing antibodies to successfully clear the virus. The current clinical trials for HCV vaccines comprise synthetic peptides, DNA-based vaccines, or recombinant protein vaccines. Several preclinical vaccine studies are under research including cell culture-derived HCV (HCVcc), HCV-like particles, and recombinant adenoviral vaccines. This mini-review will discuss the prevalence of HCV worldwide and in Egypt. We will present the recent progress in basic research and preclinical and clinical studies for HCV vaccine. Finally, it will present the phenomena of spontaneous clearance of HCV without treatment as a model for study of HCV vaccine development.

show abstract

A plant‐derived dehydrorotenoid: a new inhibitor of hepatitis C virus entry

et al. 2017

Self Cite

View full text Add to dashboard Cite

Emergence of drug-resistant viruses, high cost and adverse side-effects associated with the standard therapy against hepatitis C virus (HCV) infection demonstrate the need for development of well tolerated and effective antivirals. We identified and chemically characterised the dehydrorotenoid boeravinone H, isolated from the herb Boerhavia diffusa, as a new inhibitor of HCV entry. The compound significantly inhibits the binding and entry of hepatitis C-like particles (HCV-LPs) in hepatoma cells in vitro with no apparent cytotoxicity. Boeravinone H inhibits the initial phase of HCV entry probably by acting directly on the viral particle. Importantly, the compound prevents HCV entry and infection in cell culture (ex vivo). Thus, boeravinone H is a potential antiviral agent for the prevention and control of HCV infection.

show abstract

Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy

Cited by 23 publications

References 38 publications

Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies

Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies

Progress in Vaccine Development for HCV Infection

A plant‐derived dehydrorotenoid: a new inhibitor of hepatitis C virus entry

Contact Info

Product

Resources

About